DC-KENUP-FOUNDATION
15.11.2020 16:02:06 CET | Business Wire | Press release
On the occasion of the Annual Meeting of the American Society of Tropical Medicine and Hygiene approximately 4,900 global health professionals representing academia, government, and the private sector were informed about the latest investment of the EU Malaria Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005124/en/
The EU Malaria Fund is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.
On November 13, 2020, Sanaria received €12.9M for the development of two malaria vaccines, one malaria prophylactic, as well as an initial proof-of-concept for an oral SARS-CoV-2 vaccine.
Sanaria’s PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria. PfSPZ Vaccine elicits an immunological response in the body against the malaria pathogen, without the individual getting sick. This results in robust and durable protection. On the verge of Phase III clinical trials, PfSPZ Vaccine is positioned to be the world’s first malaria vaccine to receive marketing authorization. Sanaria’s second generation vaccine, Sanaria PfSPZ-CVac (Chemoprophylaxis Vaccine), focuses on increased potency and decreased costs. The funding also advances the research and development of human monoclonal antibodies from multiple candidates based on potency and manufacturability in order to provide immediate short-term protection against malaria. Finally, a portion of the funding will be used to advance OraCOV, an oral, self-administered vaccine candidate against COVID-19, based on Sanaria’s work in malaria.
Dr. Stephen L. Hoffman, Sanaria’s founder and CEO said, “We applaud the EU Malaria Fund for addressing this critical funding gap and we are grateful and honored to be the recipient of this investment.”
“We wholeheartedly welcome the efforts of Sanaria, who for many years have been at the forefront of innovation and are bringing novel concepts to the table potentially reducing the unacceptable burden of malaria,” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme at the online signature event.
Holm Keller, Co-Managing Director of EUMF and Chairman of kENUP Foundation said: “Sanaria has developed one of the most advanced malaria vaccine candidates worldwide. We hope that this investment will help towards the eradication of malaria “.
More information can be found at https://www.controlmalaria.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20201115005124/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 68.7.2026 00:22:00 CEST | Press release
Presented by NYU Langone Health and Powered by MerrellLottery Open Through July 20 The Empire State Building Observation Deck (ESB), atop the “World’s Most Famous Building,” today announced that general lottery registration is open for this year's Empire State Building Observation Deck Run-Up (ESBRU), which will run through July 20, 2026. The annual race, presented by NYU Langone Health and powered by Merrell, will take place on Oct. 6, 2026, at 8 p.m. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707902561/en/ Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 6 This year’s race marks the 48th anniversary of the event, in which 225 runners will race up 1,576 stairs of the iconic New York City landmark to reach the world-famous 86th Floor Observation Deck. “Every year, the Empire State Building Observation Deck Run-Up is a remarkable feat for all who participate as they race up to Tripadvi
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 20:36:00 CEST | Press release
A record-breaking sales value for a residential project in the UAEThe project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi1,700 residences sold within days after the launch15% non-UAE resident buyers81% new customers to Modon Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of laun
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release
Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 15:00:00 CEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom